Immunoprecise Antibodies Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.9163
- Today's High:
- $2
- Open Price:
- $1.98
- 52W Low:
- $1.711
- 52W High:
- $5.9
- Prev. Close:
- $2.056
- Volume:
- 18723
Company Statistics
- Market Cap.:
- $53.70 million
- Book Value:
- 2.307
- Revenue TTM:
- $20.67 million
- Operating Margin TTM:
- -126.26%
- Gross Profit TTM:
- $11.56 million
- Profit Margin:
- -128.53%
- Return on Assets TTM:
- -19.02%
- Return on Equity TTM:
- -39.91%
Company Profile
Immunoprecise Antibodies Ltd had its IPO on 2017-01-03 under the ticker symbol IPA.
The company operates in the Healthcare sector and Biotechnology industry. Immunoprecise Antibodies Ltd has a staff strength of 102 employees.
Stock update
Shares of Immunoprecise Antibodies Ltd opened at $1.98 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.92 - $2, and closed at $1.98.
This is a -3.7% slip from the previous day's closing price.
A total volume of 18,723 shares were traded at the close of the day’s session.
In the last one week, shares of Immunoprecise Antibodies Ltd have slipped by -2.46%.
Immunoprecise Antibodies Ltd's Key Ratios
Immunoprecise Antibodies Ltd has a market cap of $53.70 million, indicating a price to book ratio of 2.7541 and a price to sales ratio of 6.2771.
In the last 12-months Immunoprecise Antibodies Ltd’s revenue was $20.67 million with a gross profit of $11.56 million and an EBITDA of $-22255000. The EBITDA ratio measures Immunoprecise Antibodies Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Immunoprecise Antibodies Ltd’s operating margin was -126.26% while its return on assets stood at -19.02% with a return of equity of -39.91%.
In Q1.3333333333333, Immunoprecise Antibodies Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 7.3%.
Immunoprecise Antibodies Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.8 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immunoprecise Antibodies Ltd’s profitability.
Immunoprecise Antibodies Ltd stock is trading at a EV to sales ratio of 6.2075 and a EV to EBITDA ratio of -6.7646. Its price to sales ratio in the trailing 12-months stood at 6.2771.
Immunoprecise Antibodies Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $77.81 million
- Total Liabilities
- $5.92 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $462000
- Dividend Payout Ratio
- 0%
Immunoprecise Antibodies Ltd ended 2024 with $77.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $77.81 million while shareholder equity stood at $57.80 million.
Immunoprecise Antibodies Ltd ended 2024 with $0 in deferred long-term liabilities, $5.92 million in other current liabilities, 117470000.00 in common stock, $-73088000.00 in retained earnings and $19.17 million in goodwill. Its cash balance stood at $8.28 million and cash and short-term investments were $8.28 million. The company’s total short-term debt was $1,116,000 while long-term debt stood at $0.
Immunoprecise Antibodies Ltd’s total current assets stands at $16.79 million while long-term investments were $115000.00 and short-term investments were $0. Its net receivables were $4.42 million compared to accounts payable of $3.39 million and inventory worth $2.06 million.
In 2024, Immunoprecise Antibodies Ltd's operating cash flow was $0 while its capital expenditure stood at $462000.
Comparatively, Immunoprecise Antibodies Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.98
- 52-Week High
- $5.9
- 52-Week Low
- $1.711
- Analyst Target Price
- $7.99
Immunoprecise Antibodies Ltd stock is currently trading at $1.98 per share. It touched a 52-week high of $5.9 and a 52-week low of $5.9. Analysts tracking the stock have a 12-month average target price of $7.99.
Its 50-day moving average was $2.39 and 200-day moving average was $3.46 The short ratio stood at 0.59 indicating a short percent outstanding of 0%.
Around 169.7% of the company’s stock are held by insiders while 651.3% are held by institutions.
Frequently Asked Questions About Immunoprecise Antibodies Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.